Revelation Biosciences

REVB

Biotechnology · Healthcare

Price

$1.06

-0.01 (-0.93%)

Market Cap

$4.1M

Exchange

NASDAQ Capital Market

Winston Score

–

No score yet — Winston is napping.

We couldn’t gather enough financial data to score this stock reliably.

Share count rising — dilution

+105553.4% over 4y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 587.582 (2021) → 621K (2025)

Revelation Biosciences is a small biotechnology company focused on developing drugs that work with the immune system to prevent or treat diseases. Its main programs target infectious diseases and conditions where the immune system needs a boost, with potential customers being patients, hospitals, and public health systems. The company is in the clinical-stage, meaning none of its products have been approved for sale yet.

Revelation Biosciences makes no product revenue right now and funds its operations through equity raises and grants, which is typical for early-stage biotech firms. It operates primarily in the United States and, with a market cap near zero, is considered a micro-cap company with very limited financial resources. The biggest risk it faces is running out of cash before it can advance its drug candidates through clinical trials and reach regulatory approval, which remains a long and uncertain process.

Winston Score History

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

YoY Growth Rate

Revenue data limited

EPS Growth

-28.4% YoY

YoY Growth Rate

Earnings declining

R&D Spend

$4M/ year

↑ Rising (+15% vs prior year)

R&D investment increasing — building for the future

Insider Activity

25.9%ownership

Insiders own a meaningful stake in the company

Cash Runway

~13 months

$14M cash & investments

Quarterly Free Cash Flow

↑ Burn rate improving

Adequate runway but may need to raise capital within 2 years

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Gross Margin

N/A

Data not available

Operating Margin

N/A

Data not available

ROCE

-23.6%

Weak — -23.6% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales YoY

-100.0%

Shrinking sales (-100.0% YoY)

EPS YoY

N/A

—

Data not available

EPS Consistency

0/8 quarters

Earnings rarely grow — volatile business

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Cash Conversion

N/A

—

Data not available

FCF Margin

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

Debt / Equity

0.01

Conservative — low debt load (0.01)

Interest Cover

N/A

—

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

P/E Ratio (TTM)

N/M

—

Negative earnings — P/E not meaningful

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial